Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences, Novartis to Work with Incyte on Databases

Premium

PALO ALTO, Calif.--Earlier this month, Incyte Pharmaceuticals here announced a joint venture with Oxford GlycoSciences in which the two companies will develop proteomics databases for humans, animals, plants, and microbes. In another deal, the company also said it has entered a multiyear collaboration that gives Novartis access to Incyte's LifeSeq database.

In the proteomics venture, Incyte will contribute its genomics and bioinformatics capabilities--including database architecture and software and data analysis--and also make a $5 million investment in Oxford, which will provide proteomics technologies. The partners will share profit and intellectual property rights. The arrangement also gives Oxford access to certain Incyte databases for use in its glycobiology-based drug discovery programs, while Incyte gains access to Oxford's high-throughput protein expression analysis technology.

Meanwhile, in the deal with Novartis, Incyte will receive annual access fees for use of the database and could earn royalties on sales of products developed with LifeSeq.

Filed under

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.